Anti-PD-L1 improves barrier function and reduces CD103+ DC cell accumulation by regulating gut and lung microbiota and its metabolites to alleviate asthma in juvenile mice
Biomedical Journal · 2026-10 · 49 (5) · 100944
DOI: 10.1016/j.bj.2025.100944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Journal, 2026-10. Verfasst von Jinli Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Asthma, B7-H1 Antigen, Lung, Dendritic Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Programmed death ligand 1 (PD-L1) was found to play an important role in maintaining tolerance and immune balance, and its mechanism of action on asthma still needs to be further clarified. We aim to block PD-L1 in vivo to further clarify its potential role in the pathogenesis of asthma. MATERIAL AND METHODS: In a juvenile asthma model, PD-L1 blockers were used to inhibit the expression of PD-L1 in vivo. By evaluating parameters that reflect airway hyperresponsiveness, airway inflammation, tissue damage, intestinal barrier function, and microbiome changes in mice, the impact of PD-L1 blockade on various physiological and immune indicators in asthma models is fully revealed. RESULTS: PD-L1 blockade reduces leukocyte infiltration in the lungs, including eosinophils, decreased levels of IgE and IgG1, and restored Th1/Th2 imbalance by reducing IL-4, IL-13, and GATA-3 while increasing IFN-γ. In addition, PD-L1 blockade significantly decreased levels of IL-17A/F and increased IL-10. Histological analysis of the lungs showed that PD-L1 blockade attenuated airway inflammatory cell infiltration and mucus hyperproduction. Further testing showed that the intestinal barrier function was improved after PD-L1 blockade. Mechanistic studies revealed that PD-L1 blockade improved microbiota composition in the lungs and gut, increased Lactobacillus, SCFA, and reduced LPS. As well as induced the downregulation of CD103+ DCs in lung. Correlation analysis showed that airway inflammation is negatively correlated with SCFA and positively correlated with LPS, and barrier function is negatively correlated with LPS. CONCLUSIONS: PD-L1 blockade alleviated asthmatic airway inflammation by modulating gut and lung microbiota, improving intestinal barrier function, increasing SCFA levels, reducing LPS and CD103+ DCs activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
- Department of Geriatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. Electronic address: Huisu2014@163.com.
- Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. Electronic address: sunxin6@fmmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, J., Zhang, Y., Li, Q., Wang, M., Zhou, H., Su, H., & Sun, X. (2026). Anti-PD-L1 improves barrier function and reduces CD103+ DC cell accumulation by regulating gut and lung microbiota and its metabolites to alleviate asthma in juvenile mice. Biomedical Journal, 49(5), 100944. https://doi.org/10.1016/j.bj.2025.100944
Vancouver
Huang J, Zhang Y, Li Q, Wang M, Zhou H, Su H, et al. Anti-PD-L1 improves barrier function and reduces CD103+ DC cell accumulation by regulating gut and lung microbiota and its metabolites to alleviate asthma in juvenile mice. Biomedical Journal. 2026;49(5):100944. doi:10.1016/j.bj.2025.100944
BibTeX
@article{Huang2026,
author = {Huang, Jinli and Zhang, Yi and Li, Qiuhong and Wang, Min and Zhou, Han and Su, Hui and Sun, Xin},
title = {Anti-PD-L1 improves barrier function and reduces CD103+ DC cell accumulation by regulating gut and lung microbiota and its metabolites to alleviate asthma in juvenile mice},
journal = {Biomedical Journal},
year = {2026},
volume = {49},
number = {5},
pages = {100944},
doi = {10.1016/j.bj.2025.100944}
}
EUVIMED